Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Better Bets vs. YMAB Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Y-mAbs Therapeutics (YMAB)

Market Price (9/30/2025): $8.6 | Market Cap: $389.7 Mil
Sector: Health Care | Industry: Biotechnology

Y-mAbs Therapeutics (YMAB)

Market Price (9/30/2025): $8.6
Market Cap: $389.7 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15%		  Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -27 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -31%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -40%		  Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.3%, Rev Chg QQuarterly Revenue Change % is -14%
2   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -21%
3   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10%
0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15%
1 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -40%
2 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -27 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -31%
3 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.3%, Rev Chg QQuarterly Revenue Change % is -14%
4 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -21%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -21%
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10%

Market Valuation

 9/30/252024202320222021
Share Price CYE$8.60$7.83$6.82$4.88$16.21
Market Cap CYE ($ Mil)389.7351.4297.5213.1707.9
Total Debt ($ Mil)3.10.81.41.83.6
Total Cash ($ Mil)62.367.278.6105.8181.6
Enterprise Value ($ Mil)330.6352.2298.9214.9711.5
Valuation Ratios     
P/S TTM4.64.03.53.320.1
P/EBIT TTM-14.6-11.1-11.6-2.2-13.1
P/E TTM-17.5-11.7-13.9-2.2-12.7
Sector Ratios     
P/S TTM (Sector)3.73.64.04.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.8
P/E TTM (Sector)-1.9-1.5-1.5-1.3-2.8
 9/30/2520242023
Share Price CYE$8.60$7.83$6.82
Market Cap CYE ($ Mil)389.7351.4297.5
Total Debt ($ Mil)3.10.81.4
Total Cash ($ Mil)62.367.278.6
Enterprise Value ($ Mil)330.6352.2298.9
Valuation Ratios   
P/S TTM4.64.03.5
P/EBIT TTM-14.6-11.1-11.6
P/E TTM-17.5-11.7-13.9
Sector Ratios   
P/S TTM (Sector)3.73.64.0
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.9-1.5-1.5

Business Description

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
YMAB Return58%-67%-70%40%15%-100%�
Peers Return1%8%-9%4%-11%12%2%
S&P 500 Return16%27%-19%24%23%13%106%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: ACT, ALKS, PRGO, LIVN, PCRX.
[3] 2025 data is for the year up to 9/29/2025 (YTD)

Better Bets than Y-mAbs Therapeutics (YMAB)

 YMABBetter Performance than YMAB
MetricValueIndustry (Biotechnology)
Rev Chg LTM-1.3%ABBV (6.1%), AMGN (12.9%), GILD (3.8%), VRTX (10.5%), REGN (5.4%)
Rev Chg 3Y Avg37.9%ALNY (40.8%), BBIO (1225.0%), CYTK (824.6%), RYTM (137.5%), AXSM (699.5%)
Op Mgn LTM-31.2%ABBV (23.5%), AMGN (23.5%), GILD (37.4%), VRTX (-1.7%), REGN (27.0%)
CFO/Rev LTM-20.8%ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (33.4%)
FCF/Rev LTM-21.0%ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (25.0%)
Total Yield-5.7%ABBV (3.8%), AMGN (7.9%), GILD (7.3%), VRTX (3.6%), REGN (7.9%)
 YMABBetter Performance than YMAB
MetricValueAll Other Sectors
Rev Chg LTM-1.3%NVDA (71.6%), MSFT (14.9%), AAPL (6.0%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg37.9%NVDA (92.0%), MELI (39.8%), RCL (65.4%), APO (129.8%), NU (70.1%)
Op Mgn LTM-31.2%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), AMZN (11.4%)
CFO/Rev LTM-20.8%NVDA (46.6%), MSFT (48.3%), AAPL (26.6%), GOOGL (36.0%), AMZN (18.1%)
FCF/Rev LTM-21.0%NVDA (43.6%), MSFT (25.4%), AAPL (23.5%), GOOGL (18.0%), AMZN (2.0%)
Total Yield-5.7%NVDA (2.0%), MSFT (3.3%), AAPL (3.0%), GOOGL (4.2%), AMZN (3.0%)

Latest Trefis Analyses

TitleTopic
0DASHBOARDS 
1Y-mAbs Therapeutics (YMAB) Stock: 29% of days in last 3 months had 1% or greater fluctuation 
2Y-mAbs Therapeutics vs. S&P500 CorrelationCorrelation
3Y-mAbs Therapeutics Price VolatilityVolatility
4Day 8 of Gains Streak for Y-mAbs Therapeutics Stock with 43% Return (vs. 108% YTD) [8/22/2024]Notification
5Day 5 of Gains Streak for Y-mAbs Therapeutics Stock with 25% Return (vs. 82% YTD) [8/19/2024]Notification
6Day 6 of Loss Streak for Y-mAbs Therapeutics Stock with -30% Return (vs. 76% YTD) [5/14/2024]Notification
7Day 5 of Loss Streak for Y-mAbs Therapeutics Stock with -30% Return (vs. 77% YTD) [5/13/2024]Notification
8Day 7 of Gains Streak for Y Stock with 28% Return (vs. 143% YTD) [2/21/2024]Notification
9Day 6 of Gains Streak for Y Stock with 26% Return (vs. 139% YTD) [2/20/2024]Notification
10Day 6 of Gains Streak for Y Stock with 26% Return (vs. 139% YTD) [2/18/2024]Notification

Trade Ideas

Select past trade ideas related to YMAB and Biotechnology.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
LNTH_8312025_Dip_Buyer_High_CFO_Margins_ExInd_DE08312025LNTHLantheusDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap		-7.8%-7.8%-8.7%
COO_8312025_Monopoly_xInd_xCD_Getting_Cheaper08312025COOCooper CompaniesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		0.2%0.2%-4.6%
WST_8312025_Monopoly_xInd_xCD_Getting_Cheaper08312025WSTWest Pharmaceutical ServicesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		5.9%5.9%-1.3%
BMY_7312025_Dip_Buyer_FCFYield07312025BMYBristol-Myers SquibbDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		1.9%1.9%0.0%
UTHR_7312025_Dip_Buyer_FCFYield07312025UTHRUnited TherapeuticsDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		57.5%57.5%0.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
LNTH_8312025_Dip_Buyer_High_CFO_Margins_ExInd_DE08312025LNTHLantheusDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap		-7.8%-7.8%-8.7%
COO_8312025_Monopoly_xInd_xCD_Getting_Cheaper08312025COOCooper CompaniesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		0.2%0.2%-4.6%
WST_8312025_Monopoly_xInd_xCD_Getting_Cheaper08312025WSTWest Pharmaceutical ServicesMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		5.9%5.9%-1.3%
BMY_7312025_Dip_Buyer_FCFYield07312025BMYBristol-Myers SquibbDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		1.9%1.9%0.0%
UTHR_7312025_Dip_Buyer_FCFYield07312025UTHRUnited TherapeuticsDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin		57.5%57.5%0.0%

See Trefis Trade Ideas for more.

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1FTELFitell1068.4%-96.0%
2WOLFWolfspeed886.6%231.8%
3WHLRWheeler Real Estate Investment Trust404.4%-99.7%
4MNDRMobile-health Network Solutions388.0%-71.1%
5QUREuniQure329.5%236.4%
6NUAINew Era Energy & Digital311.7% 
7BQBoqii208.5%153.9%
8DVLTDatavault AI180.5% 
9DFLIDragonfly Energy132.9%-76.4%
10SHFSSHF130.9%-18.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1WOKWORK Medical Technology-91.5%-98.5%
2KALAKala Bio-89.0%-70.5%
3MLTXMoonLake Immunotherapeutics-88.6%-88.5%
4SDMSmart Digital-87.5%-83.8%
5NRIMNorthrim BanCorp-76.1%14.0%
6IOBTIO Biotech-75.5%-60.3%
7ZYBTZhengye Biotechnology-74.9% 
8AMBIAmbipar Emergency Response-74.0%-78.8%
9FGLFounder-63.8%-64.3%
10BINIBollinger Innovations-63.6%-100.0%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical13709.5%13709.5%
2TNFATNF Pharmaceuticals7529.9%-95.9%
3QMMMQMMM2749.6%9228.1%
4WOLFWolfspeed1757.1%231.8%
5EAFGrafTech International1199.0%-24.2%
6SEGGLottery.com646.7%-7.9%
7SLNHSoluna435.8%20.0%
8PTNMPitanium433.3% 
9NUAINew Era Energy & Digital395.6% 
10BREABrera380.3%3593.8%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1BINIBollinger Innovations-96.1%-100.0%
2WOKWORK Medical Technology-90.8%-98.5%
3CJETChijet Motor-90.3%-92.7%
4MLTXMoonLake Immunotherapeutics-88.6%-88.5%
5YAASYouxin Technology-85.8%-98.9%
6ATYRaTyr Pharma-85.1%-78.0%
7CURXCuranex Pharmaceuticals-84.9%28.8%
8YYGHYY-84.6%-80.3%
9NEONNeonode-84.6%-58.7%
10SDMSmart Digital-82.5%-83.8%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1FTELFitell1068.4%-96.0%
2WOLFWolfspeed886.6%231.8%
3WHLRWheeler Real Estate Investment Trust404.4%-99.7%
4MNDRMobile-health Network Solutions388.0%-71.1%
5QUREuniQure329.5%236.4%
6NUAINew Era Energy & Digital311.7% 
7BQBoqii208.5%153.9%
8DVLTDatavault AI180.5% 
9DFLIDragonfly Energy132.9%-76.4%
10SHFSSHF130.9%-18.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1WOKWORK Medical Technology-91.5%-98.5%
2KALAKala Bio-89.0%-70.5%
3MLTXMoonLake Immunotherapeutics-88.6%-88.5%
4SDMSmart Digital-87.5%-83.8%
5NRIMNorthrim BanCorp-76.1%14.0%
6IOBTIO Biotech-75.5%-60.3%
7ZYBTZhengye Biotechnology-74.9% 
8AMBIAmbipar Emergency Response-74.0%-78.8%
9FGLFounder-63.8%-64.3%
10BINIBollinger Innovations-63.6%-100.0%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Y-mAbs Therapeutics

Financials

YMABACTALKSPRGOLIVNPCRXMedian
NameY-mAbs T.Enact Alkermes Perrigo LivaNova Pacira B. 
Mkt Price-38.7429.0421.7352.3325.3429.04
Mkt Cap0.45.84.83.02.91.22.9
Rev LTM851,2261,5054,3261,3097061,268
Op Inc LTM-27-37441317569175
FCF LTM-18701480257162117209
FCF 3Y Avg-2564132223892143190
CFO LTM-18701521366217135291
CFO 3Y Avg-25641364342133159250

Growth & Margins

YMABACTALKSPRGOLIVNPCRXMedian
NameY-mAbs T.Enact Alkermes Perrigo LivaNova Pacira B. 
Rev Chg LTM-1.3%3.4%-0.2%-2.3%8.2%2.3%1.0%
Rev Chg 3Y Avg37.9%3.7%9.2%-0.0%8.8%4.8%6.8%
Rev Chg Q-14.4%1.9%-2.1%-0.9%10.7%1.7%0.4%
QoQ Delta Rev Chg LTM-3.7%0.5%-0.6%-0.2%2.7%0.4%0.1%
Op Mgn LTM-31.2%-24.9%9.6%13.4%9.7%9.7%
Op Mgn 3Y Avg-37.5%-22.3%6.2%7.0%11.5%7.0%
QoQ Delta Op Mgn LTM3.6%--1.0%0.3%0.7%-3.2%0.3%
CFO/Rev LTM-20.8%57.1%34.6%8.5%16.5%19.1%17.8%
CFO/Rev 3Y Avg-29.7%54.5%24.3%7.7%10.7%23.1%16.9%
FCF/Rev LTM-21.0%57.1%31.9%5.9%12.4%16.6%14.5%
FCF/Rev 3Y Avg-29.8%54.5%21.5%5.3%7.4%20.8%14.1%

Valuation

YMABACTALKSPRGOLIVNPCRXMedian
NameY-mAbs T.Enact Alkermes Perrigo LivaNova Pacira B. 
Mkt Cap0.45.84.83.02.91.22.9
P/S4.64.73.20.72.21.62.7
P/EBIT-14.66.411.410.6-23.4-12.6-3.1
P/E-17.68.613.7-37.4-13.5-9.0-11.3
P/CFO-21.98.39.28.213.28.68.4
Total Yield-5.7%13.7%7.3%-1.4%-7.4%-11.1%-3.6%
Dividend Yield0.0%2.0%0.0%1.3%0.0%0.0%0.0%
FCF Yield 3Y Avg-8.9%13.4%7.1%6.1%3.5%10.5%6.6%
D/E0.00.10.01.20.20.50.1
Net D/E-0.2-0.3-0.21.1-0.00.2-0.1

Returns

YMABACTALKSPRGOLIVNPCRXMedian
NameY-mAbs T.Enact Alkermes Perrigo LivaNova Pacira B. 
1M Rtn-2.9%0.2%-8.5%-7.2%-5.0%-5.0%
3M Rtn-4.9%1.5%-17.7%16.2%6.0%4.9%
6M Rtn-12.8%-12.1%-20.7%33.2%2.0%2.0%
12M Rtn-9.4%5.5%-11.6%-0.4%74.3%5.5%
3Y Rtn-100.7%39.9%-31.8%3.1%-52.4%3.1%
1M Excs Rtn-0.6%-2.1%-11.0%-8.1%-8.1%-8.1%
3M Excs Rtn--2.5%-5.9%-25.0%8.9%-1.3%-2.5%
6M Excs Rtn--5.5%-31.9%-40.1%14.4%-17.6%-17.6%
12M Excs Rtn--6.3%-6.5%-27.6%-15.2%65.8%-6.5%
3Y Excs Rtn-17.1%-38.2%-114.2%-71.2%-130.3%-71.2%

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/8/20255/13/20253/4/202511/8/20248/12/20245/7/20242/29/202411/13/20238/10/20235/8/20233/30/202311/7/2022
Key Financials Quarterly            
Total Revenue202126182320232021203113
Ebitda-6-6-6-8-10-7-3-8-7-7-1-26
Operating Income-6-7-6-9-10-7-3-8-7-8-1-26
Net Income-3-5-7-7-9-7-1-8-6-61-28
EPS-0.07-0.12-0.15-0.16-0.21-0.15-0.02-0.18-0.14-0.150.03-0.63
Key Financials TTM            
Total Revenue TTM858988858784859385756543
Ebitda TTM-26-30-31-28-27-24-25-23-41-74-94-129
Operating Income TTM-27-31-31-28-28-25-26-24-42-75-95-129
Net Income TTM-22-28-30-24-25-22-21-19-39-74-96-134
Growth Rates Quarterly            
Total Revenue Growth-14.4%4.9%13.4%-9.7%9.9%-1.6%-25.7%63.1%92.2%93.1%227.6%39.8%
EBITDA Growth42.4%4.1%-92.0%-11.4%-37.7%7.8%-229.1%70.6%82.4%73.4%97.4%9.7%
Operating Income Growth42.8%5.3%-85.6%-10.6%-35.5%7.9%-177.5%70.2%81.9%72.9%96.8%9.4%
Net Income Growth65.0%21.6%-587.2%9.7%-46.8%-3.7%-185.4%71.9%84.7%77.2%103.1%4.6%
Margins Quarterly            
EBITDA Margin-28.4%-31.0%-22.0%-45.8%-42.3%-33.9%-13.0%-37.1%-33.7%-36.1%-2.9%-205.7%
Operating Income Margin-28.7%-31.3%-22.4%-46.4%-42.9%-34.7%-13.7%-37.9%-34.8%-37.0%-3.7%-207.5%
Net Income Margin-16.6%-24.9%-25.6%-37.9%-40.6%-33.3%-4.2%-37.9%-30.4%-31.6%3.7%-219.6%
Cash & Debt            
Total Cash62606768787679878893106115
Total Debt311111121122
Net Debt / (Cash)-59-60-66-67-77-75-77-85-87-91-104-112
Cash Flows Quarterly            
FCF from Operations2-7-2-110-3-8-1-5-13-9-19
Cash Flows TTM            
FCF from Operations TTM-18-19-16-22-13-18-27-28-46-64-76-101
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC-4.3%-5.0%-4.2%-6.8%-8.0%-5.7%-2.7%-6.6%-6.2%-6.5%-1.0%-24.0%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-5.0%-5.8%-6.1%-5.6%-5.6%-5.1%-5.3%-5.0%-9.0%-16.3%-21.5%-29.9%

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
Product revenue, net844933  
License revenue016221 
Total85653521 


Assets by Segment
$ Mil20242023202220212020
Single segment    216
Total    216


Price Behavior

YMAB Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta-6.67-4.48-1.920.710.901.30
Up Beta-2.47-1.411.830.760.911.23
Down Beta-4.00-7.52-4.761.291.191.04
Up Capture-104%66%72%85%40%267%
Bmk +ve Days10223571142415
Stock +ve Days8172760110352
Down Capture-2211%-1245%-647%24%112%108%
Bmk -ve Days11192754106334
Stock -ve Days5152656126381

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date9152025
Short Interest: Shares Quantity1,067,630
Short Interest: % Change Since 8312025-42.4%
Average Daily Volume638,459
Days-to-Cover Short Interest1.67
Basic Shares Quantity45,318,028
Short % of Basic Shares2.4%

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/8/2025-0.1%-0.1%0.8%
5/13/20252.2%2.5%21.1%
3/4/2025-4.4%-8.3%-13.3%
11/8/2024-0.5%-25.5%-34.0%
8/12/2024-11.2%9.2%19.5%
2/29/202411.9%5.6%-3.1%
11/13/20239.8%7.6%40.4%
8/10/2023-9.9%-12.2%-16.1%
...
SUMMARY STATS   
# Positive111213
# Negative11109
Median Positive9.8%7.1%22.4%
Median Negative-4.3%-8.8%-13.3%
Max Positive52.3%74.2%87.5%
Max Negative-21.6%-25.5%-34.0%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025808202510-Q 6/30/2025
3312025513202510-Q 3/31/2025
12312024304202510-K 12/31/2024
93020241108202410-Q 9/30/2024
6302024812202410-Q 6/30/2024
3312024507202410-Q 3/31/2024
12312023229202410-K 12/31/2023
93020231113202310-Q 9/30/2023
6302023810202310-Q 6/30/2023
3312023508202310-Q 3/31/2023
12312022330202310-K 12/31/2022
93020221107202210-Q 9/30/2022
6302022808202210-Q 6/30/2022
3312022509202210-Q 3/31/2022
12312021301202210-K 12/31/2021
93020211104202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0Rossi Michael JPRESIDENT & CEO3112025Sell5.203,91720,368712,832Form
1Gad ThomasCHIEF BUSINESS OFFICER3112025Sell5.2310,81056,5361,060,231Form
2Gad ThomasCHIEF BUSINESS OFFICER9172024Sell13.4765,000875,5501,315,763Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.